Treats growth failure. Sold as Increlex. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Mecasermin Recombinant (sold as Increlex), first approved Aug 30, 2005, with 1 new use approved and 0 published complete response letters.
| A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsBronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity · OHB Neonatology Ltd. | Phase 2 | Active, not recruiting | Aug 17, 2017 |
| Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).IGF1 Deficiency · Esteve Pharmaceuticals, S.A. | — | Recruiting | May 15, 2009 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
